Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis

BACKGROUND & AIMS: Autoimmune hepatitis (AIH) is a disease of unknown aetiology with a favourable response to immunosuppression. However, in the clinic, it appears that <50% of patients achieve complete response on standard treatment. Serum B cell-activating factor (BAFF) levels are elevated...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JHEP Rep
Asıl Yazarlar: Arvaniti, Pinelopi, Giannoulis, George, Gabeta, Stella, Zachou, Kalliopi, Koukoulis, George K., Dalekos, George N.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2020
Konular:
Short Communication
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7340979/
https://ncbi.nlm.nih.gov/pubmed/32671332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhepr.2020.100123
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller